Leo Pharma is acquiring Bayer’s dermatology unit with 450 employees

 Leo Pharma is acquiring Bayer’s dermatology unit with 450 employees

Leo Pharma is acquiring Bayer’s dermatology unit with 450 employees

Shots:
  • The agreement includes drug for treatment of acne, fungal skin infections and rosacea, and a range of topical steroids summing up an annual turnover of ≥280 Mn Euros in 2017
  •  Leo will have global product rights including sales, marketing in 14 countries except Afghanistan and Pakistan and a manufacturing site in Italy
  • Acquisition closure will be during 2018 in the US and during H2’19 for RoW
Click here to read full press release/ article | Ref: Bayer | Image: Forbes

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post